Relative to substitution of biological products by pharmacies.
Impact
The bill's passage would significantly alter existing pharmacy practices related to the dispensation of biological products. By allowing pharmacists to substitute interchangeable biologics, it would encourage the use of potentially lower-cost alternatives, thereby improving affordability for patients. However, it mandates that pharmacists inform patients when substitutions occur and make necessary electronic entries to notify prescribers, ensuring transparency and safety in patient care. This modernization of pharmacy laws aligns New Hampshire with current federal standards regarding biological product interchangeability.
Summary
House Bill 1365 aims to regulate the substitution of biological products by pharmacists in New Hampshire. It permits pharmacists to substitute one interchangeable biological product for another, given that the product has been licensed as interchangeable by the federal Food and Drug Administration (FDA). The bill seeks to enhance patient access to therapies by allowing pharmacists more flexibility in dispensing biologics that meet FDA interchangeability standards. This legislation is positioned to streamline pharmacy practices and promote cost-effective therapeutic options for patients.
Sentiment
Sentiment surrounding HB 1365 appears largely supportive among healthcare professionals and pharmacy advocates, who view it as a step toward improving access to essential medications. The bill resonates with proponents of healthcare affordability, as it can facilitate lower drug costs through increased competition among biologic products. However, caution is also noted, as some stakeholders express concern about the implications for patient safety and the integrity of prescriber authority, possibly indicating a division among those prioritizing patient access versus those prioritizing provider discretion.
Contention
One notable point of contention during discussions centered on the extent of pharmacists' authority to substitute prescribed biologics without explicit consent from the prescriber. Some legislators highlighted the importance of ensuring that healthcare providers retain the necessary control over patient treatment decisions. Opponents of the bill argue that the automatic substitution could undermine the prescribing physician's judgments, particularly when dealing with complex therapies where individual patient needs might vary significantly. This debate reflects broader themes in healthcare policy regarding the balance between efficiency, cost control, and patient-centered care.
Requires that pharmacists get express written consent before substituting a drug product for a less expensive drug product, including biological products.
Amends the types of products which pharmacists may prescribe as substitute drugs or products to include "devices and supplies" and "therapeutically equivalent drugs and pharmaceuticals".
Amends the types of products which pharmacists may prescribe as substitute drugs or products to include "devices and supplies" and "therapeutically equivalent drugs and pharmaceuticals."
AN ACT Relating to reducing prescription drug costs by eliminating barriers impeding access to biosimilar medicines and interchangeable biological products;
(New Title) relative to the practice of pharmacy, the dispensing of certain medications by pharmacists, and permitting treatment of certain severe illness under the right to try act.